1
|
Feng J, Yuan RF, Tang HL, Bai QX, Yang L, Dong HJ, Liang R, Zhang T, Gu HT, Gao GX. [Efficacy and Safety of Venetoclax-Based Induction Therapy in Acute Myeloid Leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2023; 31:960-966. [PMID: 37551462 DOI: 10.19746/j.cnki.issn.1009-2137.2023.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 08/09/2023]
Abstract
AbstractObjective: To investigate the efficacy and safety of venetoclax-based induction chemotherapy in newly diagnosed (ND) patients ineligible for intensive therapy and patients with relapsed/refractory (R/R) acute myeloid leukemia (AML). METHODS The clinical data of 51 newly diagnosed patients ineligible for intensive therapy and patients with R/R AML treated in the Department of Hematology of Xijing Hospital from February 1, 2021 to April 30, 2022 were retrospectively analyzed. The incidence of complete remission (CR)/CR with incomplete hematological recovery (CRi), objective remission rate (ORR), minimal residual disease (MRD) status, advense events (AE), overall survival (OS) and progression-free survival (PFS) were analyzed. RESULTS Among 51 patients, 32 patients were newly diagnosed patients unfit for intensive therapy, with a median age of 60 (29-88) years, and 19 patients were R/R patients, with a median age of 49 (22-92) years. The median cycles of VEN-based treatment in the two groups were both 2. The CR/CRi rates in the ND-AML and R/R-AML group after one course of induction treatment were 65.6% and 36.9%, respectively, and the ORR were 81.3% and 42.1%, respectively. The cumulative CR/CRi rates after 1-3 courses of VEN-based treatment were 71.9% and 47.4%, respectively. The MRD negativity rates of patients achieving CR/CRi were 69.6% and 33.3%, respectively. In the ND-AML and R/R-AML group, the median PFS were 8(5-11) and 3(1-5) months, and the median OS were 13 (6-20) and 5 (3-7) months, respectively. The median OS of patients achieving CR/CRi in both groups was significantly better than that of patients not achieving CR/CRi (13 months vs 4 months; OS not reached vs 4 months). During the first induction cycle, the incidence of grade 3 or higher granulocytopenia, anemia and thrombocytopenia was 96%, 90.2% and 84.3%, respectively. 30 patients (58.8%) had granulocytopenia with fever. The most common non-hematological AE was infection (12/51, 23.5%), followed by gastrointestinal symptoms (6/51, 11.8%). CONCLUSION The VEN-based strategy has good treatment response and tolerance in newly diagnosed patients unfit for intensive therapy and R/R AML. The most common AEs are hematological toxicities and infection.
Collapse
Affiliation(s)
- Juan Feng
- Department of Hematology, Xijing Hospital, Air Force Medical University, Xi'an 710032, Shannxi Province, China
| | - Rui-Feng Yuan
- Department of Hematology, Xijing Hospital, Air Force Medical University, Xi'an 710032, Shannxi Province, China
| | - Hai-Long Tang
- Department of Hematology, Xijing Hospital, Air Force Medical University, Xi'an 710032, Shannxi Province, China
| | - Qing-Xian Bai
- Department of Hematology, Xijing Hospital, Air Force Medical University, Xi'an 710032, Shannxi Province, China
| | - Lan Yang
- Department of Hematology, Xijing Hospital, Air Force Medical University, Xi'an 710032, Shannxi Province, China
| | - Hong-Juan Dong
- Department of Hematology, Xijing Hospital, Air Force Medical University, Xi'an 710032, Shannxi Province, China
| | - Rong Liang
- Department of Hematology, Xijing Hospital, Air Force Medical University, Xi'an 710032, Shannxi Province, China
| | - Tao Zhang
- Department of Hematology, Xijing Hospital, Air Force Medical University, Xi'an 710032, Shannxi Province, China
| | - Hong-Tao Gu
- Department of Hematology, Xijing Hospital, Air Force Medical University, Xi'an 710032, Shannxi Province, China
| | - Guang-Xun Gao
- Department of Hematology, Xijing Hospital, Air Force Medical University, Xi'an 710032, Shannxi Province, China,E-mail:
| |
Collapse
|
2
|
Wang JY, Chen JF, Wang SF, Guo QH, Ma YP. [Clinical Characteristics and Survival Analysis of Patients with Chronic Myelomonocytic Leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2023; 31:476-482. [PMID: 37096522 DOI: 10.19746/j.cnki.issn.1009-2137.2023.02.024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 04/26/2023]
Abstract
OBJECTIVE To investigate the clinical characteristics, prognostic factors and efficacy of hypomethylating agent (HMA) in patients with chronic myelomonocytic leukemia (CMML). METHODS The clinical data of 37 newly diagnosed patients with CMML was analyzed retrospectively, and their clinical characteristics and the efficacy of HMA were summarized. Kaplan-Meier and Log-rank test were used for univariate survival analysis, and Cox proportional hazards regression model was used for multivariate analysis. RESULTS The median age at diagnosis was 67 years old. Their common manifestations included fatigue, bleeding, abnormal blood routine and fever. Most patients had splenomegaly. According to FAB classification, there were 6 cases of myelodysplastic CMML and 31 cases of myeloproliferative CMML, while according to WHO classification, 8 patients belonged to CMML-0, 9 patients to CMML-1 and 20 patients to CMML-2. At the time of diagnosis, the median white blood cell count was 32.84×109/L, median hemoglobin (Hb) was 101 g/L, median platelet count was 65×109/L, median absolute monocyte count was 9.53×109//L, median absolute neutrophil count (ANC) was 11.29×109//L and median lactate dehydrogenase (LDH) was 374 U/L. Cytogenetic abnormalities were found in 4 cases among the 31 patients who underwent karyotype analysis or fluorescence in situ hybridization detection. There were 12 patients who had analyzable results and gene mutations were identified in 11 cases, including ASXL1, NRAS, TET2, SRSF2 and RUNX1. Among the 6 patients who were treated with HMA and could be evaluated for efficacy, 2 patients achieved complete remission, 1 patient achieved partial remission and 2 patients achieved clinical benefit. Compared with the non-HMA treatment group, overall survival (OS) time was not significantly prolonged in the HMA treatment group. Univariate analysis showed that Hb<100 g/L, ANC≥12×109/L, LDH≥250 U/L and peripheral blood (PB) blasts ≥5% were significantly associated with poor OS, while WHO classification CMML-2, Hb<100 g/L, ANC≥12×109/L, LDH≥250 U/L and PB blasts≥5% were significantly associated with poor leukemia-free survival (LFS) (P<0.05). Multivariate analysis showed that ANC≥12×109/L and PB blasts≥5% were significantly associated with poor OS and LFS (P<0.05). CONCLUSION CMML has high heterogeneity in clinical characteristics, genetic changes, prognosis and treatment response. HMA can not significantly improve the survival of CMML patients. ANC≥12×109/L and PB blasts≥5% are independent prognostic factors of OS and LFS in patients with CMML.
Collapse
Affiliation(s)
- Jing-Yu Wang
- The Second Clinical Medical College of Shanxi Medical University; Taiyuan 030000, Shanxi Province, China
| | - Jian-Fang Chen
- Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan 030000, Shanxi Province, China
| | - Shi-Fang Wang
- The Second Clinical Medical College of Shanxi Medical University; Taiyuan 030000, Shanxi Province, China
| | - Qiao-Hua Guo
- The Second Clinical Medical College of Shanxi Medical University; Taiyuan 030000, Shanxi Province, China
| | - Yan-Ping Ma
- Department of Hematology, The Second Hospital of Shanxi Medical University, Taiyuan 030000, Shanxi Province, China.E-mail:
| |
Collapse
|